skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Download your complimentary Japan Pharma Outlook 2027 report extract. The 16-page excerpt includes highlights from the full report, which is available to subscribers of Datamonitor Healthcare, and available to purchase on our Report Store.


Inside this executive summary, you’ll find:

  • Sales forecast data for 10 representative Japanese companies in PharmaVitae’s Japan Pharma peer set through 2027* (hint: it’s huge).
  • How these companies are set to meet the significant challenges presented by an aging and declining Japanese population as well as and domestic pricing pressures
  • Factors driving global growth in a fast-evolving industry landscape
  • A look at the complex challenges and opportunities facing Japan Pharma
  • Japan Pharma’s changing industry landscape and how it will affect pricing in the next decade
    •
Japan Pharma Outlook 2027
Download now Purchase report

Read also

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

    By Louisa Joseph

    Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.

    Topics

    Read Blog

  • Datamonitor Healthcare: data analysis and insight

    Webinar: Outlook for NASH Therapies and Market Dynamics

    By Joseph Haas

    Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

    Topics Cell and gene therapy Drug Development Landscape Drug approval

    Full Video

  • Awareness, Datamonitor Healthcare: data analysis and insight

    Post-ESMO Podcast 2019

    Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.

    Topics Cancer Research

    Full Podcast
;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now